
BridgeBio Pharma, Inc.
BBIO·NASDAQ
Last updated as of 2026-04-21 05:30 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
BBIO stock price change
On the last trading day, BBIO stock closed at 76.68 USD, with a price change of -0.09% for the day.
Trade stock perpsTrending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreBBIO key data
Previous close76.68 USD
Market cap14.87B USD
Volume1.65M
P/E ratio-
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)-3.78 USD
Net income (FY)−724.93M USD
Revenue (FY)502.08M USD
Next report dateApr 30, 2026
EPS estimate-
Revenue estimate178.63M USD USD
Shares float166.22M
Beta (1Y)0.71

BridgeBio Pharma, Inc. overview
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Sector
Health technology
Industry
Biotechnology
CEO
Neil Kumar
Headquarters
Palo Alto
Website
bridgebio.com
Founded
2015
Employees (FY)
839
Change (1Y)
+109 +14.93%
Revenue / Employee (1Y)
598.42K USD
Net income / Employee (1Y)
−864.04K USD
BBIO stock price forecast
According to technical indicators for BBIO stock, the price is likely to fluctuate within the range of 70.27–89.71 USD over the next week. Market analysts predict that the price of BBIO stock will likely fluctuate within the range of 66.76–108.40 USD over the next months.
Based on 1-year price forecasts from 66 analysts, the highest estimate is 176.55 USD, while the lowest estimate is 80.65 USD.
For more information, please see the
BBIO stock price forecast
page.
Latest BBIO stock news
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Finviz2026-03-05 21:12:18
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
Finviz2026-03-06 15:13:14
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
Finviz2026-03-06 15:22:06
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
Finviz2026-03-06 15:25:23
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Finviz2026-03-10 19:06:55
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade
Finviz2026-03-11 01:54:58
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
Finviz2026-03-11 18:06:59
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Finviz2026-03-18 20:09:51
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
Finviz2026-03-23 11:33:56
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Finviz2026-03-23 12:03:51
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Finviz2026-03-25 11:03:53
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
Finviz2026-03-30 11:33:47
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
Finviz2026-03-30 19:33:09
BridgeBio Oncology Therapeutics, Inc. (Bbot) announced that its innovative therapy Bbo-11818, for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
老虎证券2026-04-20 20:18:02
BridgeBio Oncology Therapeutics, Inc recently revealed that the eagerly awaited updated data from its Phase I clinical trial is expected to be released in the second half of 2026.
老虎证券2026-04-20 20:18:05
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Finviz2026-03-05 21:12:18
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
Finviz2026-03-06 15:13:14
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
Finviz2026-03-06 15:22:06
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
Finviz2026-03-06 15:25:23
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Finviz2026-03-10 19:06:55
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade
Finviz2026-03-11 01:54:58
